ERBB2 and neoplasm: With respect to this, therapy strategies using a second round of injections with MD.45-HER/ζ cells 1 month after tumour cell inoculation or combined treatment with HER-2/neu peptide-specific CTL and MD.45-HER/ζ cells are under investigation in our laboratory.